Alnylam Pharmaceuticals Inc
ALNY328.160USD
-3.080-0.93%
終値 02/06, 16:00（ET）15分遅れの株価
43.25B時価総額
1010.56直近12ヶ月PER
詳細情報 Alnylam Pharmaceuticals Inc 企業名
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Alnylam Pharmaceuticals Incの企業情報
企業コードALNY
会社名Alnylam Pharmaceuticals Inc
上場日May 28, 2004
最高経営責任者「CEO」Greenstreet (Yvonne L)
従業員数2230
証券種類Ordinary Share
決算期末May 28
本社所在地675 W Kendall St
都市CAMBRIDGE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02142-1168
電話番号16175518200
ウェブサイトhttps://www.alnylam.com/
企業コードALNY
上場日May 28, 2004
最高経営責任者「CEO」Greenstreet (Yvonne L)
Alnylam Pharmaceuticals Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
78.82K
+9426.00%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.52K
+3413.00%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
29.73K
+2290.00%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+775.00%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
+775.00%
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
775.00
+775.00%
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Executive Vice President, Chief Research and Development Officer
Executive Vice President, Chief Research and Development Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
78.82K
+9426.00%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.52K
+3413.00%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
29.73K
+2290.00%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+775.00%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
+775.00%
収益内訳
通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
事業別USD
会社名
収益
比率
AMVUTTRA
685.30M
54.87%
Regeneron Pharmaceuticals
326.60M
26.15%
GIVLAARI
73.87M
5.91%
OXLUMO
52.83M
4.23%
Other
48.80M
3.91%
他の
61.62M
4.93%
地域別USD
会社名
収益
比率
United States
613.98M
49.16%
Net revenues from collaborations
351.74M
28.16%
Europe
172.67M
13.82%
Rest of World
64.43M
5.16%
Royalty revenue
46.20M
3.70%
事業別
地域別
事業別USD
会社名
収益
比率
AMVUTTRA
685.30M
54.87%
Regeneron Pharmaceuticals
326.60M
26.15%
GIVLAARI
73.87M
5.91%
OXLUMO
52.83M
4.23%
Other
48.80M
3.91%
他の
61.62M
4.93%
株主
更新時刻: Sat, Feb 7
更新時刻: Sat, Feb 7
株主統計
種類
株主統計
株主統計
比率
Capital World Investors
12.44%
Fidelity Management & Research Company LLC
12.04%
The Vanguard Group, Inc.
10.21%
Capital Research Global Investors
5.47%
BlackRock Institutional Trust Company, N.A.
4.98%
他の
54.86%
株主統計
株主統計
比率
Capital World Investors
12.44%
Fidelity Management & Research Company LLC
12.04%
The Vanguard Group, Inc.
10.21%
Capital Research Global Investors
5.47%
BlackRock Institutional Trust Company, N.A.
4.98%
他の
54.86%
種類
株主統計
比率
Investment Advisor
69.40%
Investment Advisor/Hedge Fund
23.28%
Hedge Fund
3.81%
Research Firm
2.50%
Sovereign Wealth Fund
1.70%
Pension Fund
1.30%
Bank and Trust
1.26%
Individual Investor
0.43%
Private Equity
0.23%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
1525
136.86M
103.59%
+1.39M
2025Q3
1468
132.43M
102.39%
+2.53M
2025Q2
1335
129.81M
101.55%
+2.82M
2025Q1
1292
127.17M
99.72%
-2.77M
2024Q4
1248
125.34M
101.87%
-989.05K
2024Q3
1210
126.51M
99.20%
+3.13M
2024Q2
1165
122.70M
94.98%
+5.27M
2024Q1
1152
117.38M
97.56%
-6.00M
2023Q4
1149
120.10M
100.10%
-712.55K
2023Q3
1103
121.13M
101.32%
-503.11K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Capital World Investors
16.43M
12.44%
-370.75K
-2.21%
Sep 30, 2025
Fidelity Management & Research Company LLC
15.91M
12.04%
+854.66K
+5.68%
Sep 30, 2025
The Vanguard Group, Inc.
13.51M
10.22%
+267.08K
+2.02%
Sep 30, 2025
Capital Research Global Investors
7.22M
5.47%
+31.18K
+0.43%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.59M
4.98%
+52.87K
+0.81%
Sep 30, 2025
JP Morgan Asset Management
3.87M
2.93%
+2.07M
+115.83%
Sep 30, 2025
State Street Investment Management (US)
3.08M
2.33%
-91.63K
-2.89%
Sep 30, 2025
Baillie Gifford & Co.
2.79M
2.11%
-242.53K
-8.00%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.50M
1.89%
+100.47K
+4.19%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Tue, Dec 2
更新時刻: Tue, Dec 2
銘柄名
比率
Global X Genomics & Biotechnology ETF
6.48%
ProShares Ultra Nasdaq Biotechnology
5.81%
Invesco Nasdaq Biotechnology ETF
5.77%
Franklin Genomic Advancements ETF
5.35%
iShares Biotechnology ETF
5.07%
VanEck Biotech ETF
4.56%
American Century Focused Dynamic Growth ETF
3.76%
Goldman Sachs Future Health Care Equity ETF
3.42%
First Trust NYSE Arca Biotechnology Index Fund
3.33%
Invesco NASDAQ Next Gen 100 ETF
3.28%
詳細を見る
Global X Genomics & Biotechnology ETF
比率6.48%
ProShares Ultra Nasdaq Biotechnology
比率5.81%
Invesco Nasdaq Biotechnology ETF
比率5.77%
Franklin Genomic Advancements ETF
比率5.35%
iShares Biotechnology ETF
比率5.07%
VanEck Biotech ETF
比率4.56%
American Century Focused Dynamic Growth ETF
比率3.76%
Goldman Sachs Future Health Care Equity ETF
比率3.42%
First Trust NYSE Arca Biotechnology Index Fund
比率3.33%
Invesco NASDAQ Next Gen 100 ETF
比率3.28%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
